Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck.
B Burtness - Journal of Clinical Oncology: Official Journal of the …, 2005 - europepmc.org
This is a comment on" Phase II multicenter study of the epidermal growth factor receptor
antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the …
antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the …
[引用][C] Adding Cetuximab to Chemoradiation Did Not Benefit Patients With Advanced Head and Neck Cancer: What Were the Reasons
A Eisbruch - ASCO Post, 2014
Approval summary: cetuximab in combination with cisplatin or carboplatin and 5‐fluorouracil for the first‐line treatment of patients with recurrent locoregional or …
MH Cohen, H Chen, S Shord, C Fuchs, K He… - The …, 2013 - academic.oup.com
Abstract Learning Objectives Compare survival outcomes among patients with SCCHN
treated with a platinum/5‐FU regimen with and without cetuximab. Compare adverse event …
treated with a platinum/5‐FU regimen with and without cetuximab. Compare adverse event …
[HTML][HTML] A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic …
P Bossi, R Miceli, LD Locati, D Ferrari, S Vecchio… - Annals of …, 2017 - Elsevier
Abstract Background B490 (EudraCT# 2011-002564-24) is a randomized, phase 2b,
noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin …
noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin …
Concurrent cetuximab versus platinum‐based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer
Background The purpose of this study was to present our experience utilizing cetuximab and
platinum‐based concurrent chemoradiotherapy for the definitive treatment of head and neck …
platinum‐based concurrent chemoradiotherapy for the definitive treatment of head and neck …
Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
M Merlano, M Occelli - Therapeutics and clinical risk management, 2007 - Taylor & Francis
Cetuximab is a monoclonal antibody able to inhibit and to degrade the transmembrane
receptor Her-1, also known as epidermal growth factor receptor (EGFR). The inhibition of …
receptor Her-1, also known as epidermal growth factor receptor (EGFR). The inhibition of …
Retrospective evaluation of concomitant cetuximab and radiotherapy tolerance for locoregional advanced head and neck squamous cell carcinoma treatment in …
A Rambeau, R Gervais, D De Raucourt, E Babin… - European Archives of …, 2017 - Springer
Radiotherapy associated with cetuximab (Cet-RT) is an alternative treatment to platinum-
based chemoradiotherapy in locally advanced head and neck carcinoma (LAHNC) …
based chemoradiotherapy in locally advanced head and neck carcinoma (LAHNC) …
Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and …
T Kuhnt, A Schreiber, A Pirnasch… - Strahlentherapie …, 2017 - search.proquest.com
Background Cetuximab (CET) is a potent inhibitor of the epidermal growth factor receptor
and has been shown to have activity in squamous cell carcinoma of the head and neck …
and has been shown to have activity in squamous cell carcinoma of the head and neck …
[HTML][HTML] Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck
Background To investigate the safety and activity of cetuximab in the pre-operative treatment
of squamous cell carcinoma of the head and neck (SCCHN). Patients and methods …
of squamous cell carcinoma of the head and neck (SCCHN). Patients and methods …
Chemoradiotherapy in head and neck squamous cell carcinoma: focus on targeted therapies
A Bozec, J Thariat, RJ Bensadoun… - … : Journal de la Societe …, 2008 - europepmc.org
Radiotherapy is an essential treatment for many patients with head and neck squamous cell
carcinoma. Its association with molecular targeted therapies represents a real progress …
carcinoma. Its association with molecular targeted therapies represents a real progress …